FY2025 EPS Estimates for Globus Medical, Inc. Increased by Zacks Research (NYSE:GMED)

Globus Medical, Inc. (NYSE:GMED) – Equities research analysts at Zacks Research raised their FY2025 earnings estimates for shares of Globus Medical in a research report issued on Monday, May 6th. Zacks Research analyst R. Department now forecasts that the medical device company will earn $2.89 per share for the year, up from their prior forecast of $2.88. The consensus estimate for Globus Medical’s current full-year earnings is $2.69 per share. Zacks Research also issued estimates for Globus Medical’s Q4 2025 earnings at $0.67 EPS.

Globus Medical (NYSE:GMED) last announced its earnings results on Tuesday, February 20th. The medical device company reported $0.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.59 by $0.01. Globus Medical had a net margin of 7.83% and a return on equity of 8.82%. The firm had revenue of $616.53 million for the quarter, compared to analyst estimates of $608.21 million. During the same quarter in the prior year, the business posted $0.59 EPS. The business’s revenue was up 124.6% compared to the same quarter last year.

Other research analysts have also recently issued reports about the stock. Stifel Nicolaus lifted their price objective on shares of Globus Medical from $61.00 to $64.00 and gave the company a “buy” rating in a research note on Wednesday, February 21st. Truist Financial lifted their price objective on shares of Globus Medical from $58.00 to $60.00 and gave the company a “hold” rating in a research note on Wednesday, February 21st. Royal Bank of Canada reissued an “outperform” rating and issued a $70.00 price objective on shares of Globus Medical in a research note on Thursday, January 11th. Finally, BTIG Research raised shares of Globus Medical from a “neutral” rating to a “buy” rating and set a $60.00 price objective on the stock in a research note on Monday, March 18th. Four investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, Globus Medical presently has an average rating of “Moderate Buy” and an average target price of $66.33.

Globus Medical Stock Performance

Shares of NYSE:GMED opened at $51.36 on Wednesday. The company has a quick ratio of 2.72, a current ratio of 4.88 and a debt-to-equity ratio of 0.10. The firm has a market cap of $6.95 billion, a PE ratio of 43.90, a PEG ratio of 1.53 and a beta of 1.11. The company’s 50 day moving average price is $52.36 and its two-hundred day moving average price is $51.19. Globus Medical has a 12-month low of $43.38 and a 12-month high of $62.88.

Insider Buying and Selling at Globus Medical

In other Globus Medical news, Director Leslie V. Norwalk sold 10,590 shares of the firm’s stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $51.99, for a total value of $550,574.10. Following the sale, the director now owns 17,419 shares in the company, valued at $905,613.81. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 24.30% of the company’s stock.

Hedge Funds Weigh In On Globus Medical

A number of hedge funds have recently modified their holdings of GMED. DekaBank Deutsche Girozentrale acquired a new position in shares of Globus Medical during the third quarter worth $28,000. YHB Investment Advisors Inc. acquired a new position in shares of Globus Medical during the first quarter worth $50,000. Allworth Financial LP lifted its holdings in shares of Globus Medical by 25.7% during the fourth quarter. Allworth Financial LP now owns 1,242 shares of the medical device company’s stock worth $66,000 after purchasing an additional 254 shares during the period. Mather Group LLC. acquired a new position in shares of Globus Medical during the first quarter worth $69,000. Finally, Nisa Investment Advisors LLC lifted its holdings in shares of Globus Medical by 122.8% during the third quarter. Nisa Investment Advisors LLC now owns 1,493 shares of the medical device company’s stock worth $74,000 after purchasing an additional 823 shares during the period. Institutional investors and hedge funds own 95.16% of the company’s stock.

Globus Medical Company Profile

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.